LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.Learn More
We are focused on building out a pipeline based on disease relevance to our target markets and the ability to impact patients with transformative mechanisms and precision-based therapeutics. We select programs with a strong scientific basis and clinical data and collaborate with world-class partners across a diverse array of therapeutic areas.See All
There are over 290 million people in China with cardiovascular disease and more than 100 million with chronic kidney disease. Cardiorenal disease is the leading cause of death in China today.
5.5 people die from cancer every minute in China alone and every year there are more than 4.5 million new cases diagnosed.
June 2, 2021
Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets
May 17, 2021
Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets
May 12, 2021
Nanobiotix Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumore Types and Therapeutic Combinations in China and Other Asian Markets
May 10, 2021
LianBio Appoints Yizhe Wang, Ph.D., as Chief Executive Officer